During the last session, Emergent Biosolutions Inc (NYSE:EBS)’s traded shares were 1.12 million, with the beta value of the company hitting 1.20. At the end of the trading day, the stock’s price was $2.29, reflecting an intraday gain of 0.88% or $0.02. The 52-week high for the EBS share is $13.67, that puts it down -496.94 from that peak though still a striking 37.99% gain since the share price plummeted to a 52-week low of $1.42. The company’s market capitalization is $119.54M, and the average intraday trading volume over the past 10 days was 1.12 million shares, and the average trade volume was 3.08 million shares over the past three months.

Emergent Biosolutions Inc (NYSE:EBS) trade information

Emergent Biosolutions Inc (EBS) registered a 0.88% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.88% in intraday trading to $2.29, hitting a weekly high. The stock’s 5-day price performance is -9.49%, and it has moved by -29.75% in 30 days. Based on these gigs, the overall price performance for the year is -76.82%. The short interest in Emergent Biosolutions Inc (NYSE:EBS) is 4.91 million shares and it means that shorts have 0.74 day(s) to cover.

Emergent Biosolutions Inc (EBS) estimates and forecasts

Statistics show that Emergent Biosolutions Inc has underperformed its competitors in share price, compared to the industry in which it operates. Emergent Biosolutions Inc (EBS) shares have gone down -21.84% during the last six months, with a year-to-date growth rate less than the industry average at -124.40% against 13.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 73.80% this quarter and then jump 40.60% in the quarter after that. In the rating firms’ projections, revenue will decrease -2.30% compared to the previous financial year.

Revenue for the current quarter is expected to be $224.5 million as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to $244.5 million by the end of Jun 2024.

While earnings are projected to return 67.90% in 2024.

EBS Dividends

Emergent Biosolutions Inc is due to release its next quarterly earnings between May 07 and May 13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Emergent Biosolutions Inc (NYSE:EBS)’s Major holders

Emergent Biosolutions Inc insiders own 2.89% of total outstanding shares while institutional holders control 79.26%, with the float percentage being 81.62%. Blackrock Inc. is the largest shareholder of the company, while 182 institutions own stock in it. As of Jun 29, 2023, the company held over 9.23 million shares (or 17.82% of all shares), a total value of $67.85 million in shares.

The next largest institutional holding, with 6.79 million shares, is of State Street Corporation’s that is approximately 13.11% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $49.94 million.

Also, the Mutual Funds coming in first place with the largest holdings of Emergent Biosolutions Inc (EBS) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Aug 30, 2023 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 4.9 million shares. This amounts to just over 9.46 percent of the company’s overall shares, with a $22.99 million market value. The same data shows that the other fund manager holds slightly less at 1.44 million, or about 2.79% of the stock, which is worth about $10.61 million.